Amyris (AMRS) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AMYRIS, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
August 9, 2022 8:00 AM EDTRecord consumer revenue of $43 million increased 108% compared to Q2 2021Ingredients sold out in first half with $15 million backlog to be supplied in H2Cost actions and price increases to deliver $50 million of EBITDA improvements in H2$700 million non-equity funding and earnout provides liquidity to sustained profitability
EMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM... More
